Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan's Astellas Unveils Strategies For China

This article was originally published in PharmAsia News

Executive Summary

Astellas, Japan's second largest pharmaceutical manufacturer, is convinced that China's healthcare reforms will provide great opportunities for all pharmaceutical producers. Even though the Chinese market is now dominated by European and American companies, Astellas China revealed it will increase local new drug R&D and expand its distribution networks. Although slated reforms encourage pharmaceutical firms to focus on rural areas and low-profit drugs, Astellas will focus on patent and prescription drugs because the company believes that rural residents will still choose high quality drugs to reduce total medical care expenses. In addition, the company plans to acquire local pharmaceutical firms, but will proceed cautiously with this long-term strategy. Astellas has posted 20 percent annual growth in China over the past two years, with the market contributing to about 47 percent of its Asian revenue in the first half of 2009. (Click here for more - Chinese Language)

You may also be interested in...

QUOTED. 22 October. Robert Ford.

Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.

China Regulatory Express: Biosecurity Law, Export Controls And The Life Science Sector

With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.

Mediocre Vaccine Could Make Pandemic Worse, Non-Profit Group Tells US FDA

Ahead of the vaccine advisory committee, requests to FDA range from public health groups opposing emergency use authorizations to industry seeking labeling guidance on EUA products.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts